Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5946473 | 1.00 | ALDH1A1 (0.40) | ALDH1A1TDP1MAPTUSP2GAA | |
| SCHEMBL5946474 | 1.00 | ALDH1A1 (0.40) | ALDH1A1TDP1MAPTUSP2GAA | |
| SCHEMBL6294156 | 0.77 | ALDH1A1 (0.31) | ALDH1A1TDP1 | |
| SCHEMBL1809828 | 0.76 | — | — | |
| SCHEMBL1809829 | 0.76 | — | — | |
| SCHEMBL1809831 | 0.76 | — | — | |
| SCHEMBL21242271 | 0.73 | — | — | |
| SCHEMBL19090010 | 0.73 | ALDH1A1 (0.70) | ALDH1A1TDP1MAPTUSP2GAA | |
| SCHEMBL15945538 | 0.73 | ALDH1A1 (0.32) | ALDH1A1TDP1MAPTUSP2GAA | |
| SCHEMBL2656499 | 0.72 | ALDH1A1 (0.36) | ALDH1A1TDP1MAPTCYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11207420-B2 | Cytotoxin and conjugate, uses of same and preparation method therefor | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2021-12-28 | — | — | US | disclosed |
| US-20200179529-A1 | CYTOTOXIN AND CONJUGATE, USES OF SAME AND PREPARATION METHOD THEREFOR | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2020-06-11 | — | — | US | disclosed |
| EP-3617221-A1 | CYTOTOXIN AND CONJUGATE, USES OF SAME, AND PREPARATION METHOD THEREFOR | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2020-03-04 | — | — | EP | disclosed |
| EP-2496556-B1 | ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2018-12-26 | — | — | EP | disclosed |
| US-9018383-B2 | Acylamino-substituted cyclic carboxylic acid derivatives and their use as pharmaceuticals | SANOFI (FR) | 2015-04-28 | — | — | US | disclosed |
| US-20140088158-A1 | ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2014-03-27 | — | — | US | disclosed |
| US-8618304-B2 | Acylamino-substituted cyclic carboxylic acid derivatives and their use as pharmaceuticals | SANOFI (FR) | 2013-12-31 | — | — | US | disclosed |
| CN-102858745-A | Acylamino-substituted cyclic carboxylic acid derivatives and their use as medicaments | SANOFI AVENTIS | 2013-01-02 | — | — | CN | disclosed |
| US-20120264790-A1 | ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2012-10-18 | — | — | US | disclosed |
| EP-1569915-A4 | SPIROCYCLIC UREAS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK & CO INC (US) | 2007-07-11 | — | — | EP | disclosed |
| US-20060116366-A1 | Spirocyclic ureas, compositions containing such compounds and methods of use | MERCK & CO., INC. | 2006-06-01 | — | — | US | disclosed |
| EP-1569915-A2 | SPIROCYCLIC UREAS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | Merck & Co., Inc. (US) | 2005-09-07 | — | — | EP | disclosed |
| WO-2004050039-A2 | SPIROCYCLIC UREAS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK & CO., INC. (US) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11207420-B2 | Cytotoxin and conjugate, uses of same and preparation method therefor | CD2, HAVCR2, CD4 | ALDH1A1 3938/4885TDP1 3071/4885MAPT 2420/4885 |
| US-20120264790-A1 | ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | LPAR2, LIPG, EDF1 | ALDH1A1 1362/4885TDP1 3549/4885MAPT 4725/4885 |
| US-20060116366-A1 | Spirocyclic ureas, compositions containing such compounds and methods of use | UTS2R, GLP1R, GCGR | ALDH1A1 3232/4885TDP1 4822/4885MAPT 2992/4885 |
| US-20200179529-A1 | CYTOTOXIN AND CONJUGATE, USES OF SAME AND PREPARATION METHOD THEREFOR | CD2, HAVCR2, CD4 | ALDH1A1 3938/4885TDP1 3071/4885MAPT 2420/4885 |
| US-20140088158-A1 | ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | LPAR2, LIPG, EDF1 | ALDH1A1 1362/4885TDP1 3549/4885MAPT 4725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.